Actively Recruiting
Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT
Led by University of Rome Tor Vergata · Updated on 2026-03-04
25
Participants Needed
1
Research Sites
158 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to evaluate the role of early response assessment by 18F-FDG PET/CT in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma with PD-L1 CPS \>1 treated with pembrolizumab monotherapy, in accordance with routine clinical practice.
CONDITIONS
Official Title
Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histological diagnosis of recurrent and/or metastatic head and neck squamous cell carcinoma not suitable for curative surgery or radiotherapy and eligible for first-line systemic treatment
- PD-L1 combined positive score (CPS) of 1 or higher
You will not qualify if you...
- Any contraindication to immune checkpoint inhibitors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tor Vergata University Hospital
Rome, Italy, Italy, 00133
Actively Recruiting
Research Team
V
Vincenzo Formica, Professor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here